Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Hormonal Antineoplastic Agents. Found 26 abstracts

no pagination
Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015 Jan 15;17:6.   PMCID: 4336497
Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. Clinical Cancer Research. 2014 Dec;20(24):6379-88.   PMCID: 4299458
Balaburski GM, Dardes RC, Johnson M, Haddad B, Zhu F, Ross EA, Sengupta S, Klein-Szanto A, Liu H, Lee ES, Kim H, Jordan VC. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010 Aug;37(2):387-98.   PMCID: PMC3023309
Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 2009 Jul;27(19):3177-84.   PMCID: PMC2716939
Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008 Jan;44(1):30-8.   PMCID: PMC2566958
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008 Apr;8(2):124-33.
Uzzo RG, Haas NB, Crispen PL, Kolenko VM. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer. 2008 Apr 15;112(8):1660-71.
Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 2007 Nov;72(13):829-42.
Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiology, Biomarkers and Prevention. 2007 Nov;16(11):2207-9.
Jordan VC. Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't. Journal of the National Cancer Institute. 2007 Nov 21;99(22):1655-7.
O'Sullivan MJ, Morrow M. Ductal carcinoma in situ--current management. Surgical Clinics of North America. 2007 Apr;87(2):333-51.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British journal of pharmacology. 2006 Jan;147 Suppl 1:S269-76.
Jordan VC, Knudson AG. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology (Williston Park). 2006 May;20(6):553-62; discussion 567-8, 573, 577.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. Journal of Clinical Oncology. 2004 Jun;22(11):2133-40.
Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol. 2002 Feb 15;20(4):1115-27.
Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clinical therapeutics. 2002 Jan;24 Suppl A:A31-40.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Hormonal Antineoplastic Agents

Hormonal Antineoplastic Agents Female Breast Neoplasms therapeutic use drug therapy Tamoxifen Male Prostatic Neoplasms metabolism Neoplasm Drug Resistance Aged Middle Aged Treatment Outcome drug effects Selective Estrogen Receptor Modulators prevention & control pathology pharmacology mortality Combined Modality Therapy 80 and over Aged Androgen Antagonists Ki-67 Antigen adverse effects Adult Human Prognosis tu [Therapeutic Use] analogs & derivatives Tumor Biomarkers Estrogens Estrogen Receptor Modulators administration & dosage physiology genetics 20th Century History analysis Gene Expression Tumor Suppressor Protein p53 Tumor Cell Line Estrogen Antagonists therapy Estradiol Mice su [Surgery] Aromatase Inhibitors Neoplastic Gene Expression Regulation Prostate-Specific Antigen Chemoprevention history Cell Death 21st Century History Rats blood Hormonal) 0 (Antineoplastic Agents Proto-Oncogene Proteins c-mdm2 chemistry Raloxifene radiotherapy 10540-29-1 (Tamoxifen) Adjuvant Chemotherapy Anticarcinogenic Agents Neoplasm Grading chemically induced Kaplan-Meier Estimate Drug Dose-Response Relationship Apoptosis Clinical Trials as Topic Immunohistochemistry Experimental Mammary Neoplasms Proportional Hazards Models Differentiation Antigens Pain deficiency Proto-Oncogene Proteins c-bcl-2 Survivors Drug Interactions Biological Models Follow-Up Studies Premenopause Liver Prospective Studies Protein Transport Gene Silencing Analysis of Variance adverse methods Epidermal Growth Factor Receptor Adenocarcinoma Randomized Controlled Trials US Gov't Support-PHS Phase III Clinical Trials as Topic Radiotherapy STAT2 Transcription Factor effects Retrospective Studies US Gov't Support-Non-PHS STAT1 Transcription Factor Predictive Value of Tests Biomedical Research Estrogen Receptors Case Report BRCA1 Genes Evidence-Based Medicine di [Diagnosis] Non-US Gov't Support Treatment Failure Goserelin Intracellular Space Cyclin-Dependent Kinase Inhibitor p16 Risk Factors Interferons pharmacokinetics Conformal Radiotherapy Neoplasm Invasiveness Biological Tumor Markers Disease-Free Survival Signal Transduction trends Carcinoma in Situ NIH Research Support-Extramural Neoplasm Staging Portraits as Topic Vomiting Survival Rate antagonists & inhibitors Medical Oncology Nausea Proton Therapy Cell Proliferation Adjuvant Radiotherapy Cell Movement rt [Radiotherapy] ethnology Computer-Assisted Image Interpretation Estramustine Time Factors Drug Administration Schedule Sentinel Lymph Node Biopsy Osteoporosis dt [Drug Therapy] Neoplasm Metastasis Gene Knockdown Techniques Jews me [Metabolism] Estrogen Receptor alpha Thrombosis Down-Regulation Risk ROC Curve
Last updated on Friday, August 07, 2020